HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force.

[1]  L. Smeeth,et al.  Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. , 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  N. Gatto,et al.  The Structured Process to Identify Fit‐For‐Purpose Data: A Data Feasibility Assessment Framework , 2021, Clinical pharmacology and therapeutics.

[4]  M. Berger,et al.  How Can We Make More Rapid Progress in the Leveraging of Real-World Evidence by Regulatory Decision Makers? , 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  H. Eichler,et al.  Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance. , 2021, Journal of comparative effectiveness research.

[6]  S. Schneeweiss,et al.  STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies , 2021, BMJ.

[7]  S. Schneeweiss,et al.  Emulating Randomized Clinical Trials with Nonrandomized Real-World Evidence Studies: First Results from the RCT DUPLICATE Initiative. , 2020, Circulation.

[8]  S. Langan,et al.  Retraction of COVID-19 Pharmacoepidemiology Research Could Have Been Avoided by Effective Use of Reporting Guidelines , 2020, Clinical epidemiology.

[9]  Wim Goettsch,et al.  Improving transparency to build trust in real‐world secondary data studies for hypothesis testing—Why, what, and how: recommendations and a road map from the real‐world evidence transparency initiative , 2020, Pharmacoepidemiology and drug safety.

[10]  Nancy A Dreyer,et al.  The Certainty Framework for Assessing Real‐World Data in Studies of Medical Product Safety and Effectiveness , 2020, Clinical pharmacology and therapeutics.

[11]  Amit N. Patel,et al.  Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621. , 2020, The New England journal of medicine.

[12]  Amit N. Patel,et al.  RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis , 2020, The Lancet.

[13]  S. Schneeweiss,et al.  Emulation Differences vs. Biases When Calibrating Real‐World Evidence Findings Against Randomized Controlled Trials , 2020, Clinical pharmacology and therapeutics.

[14]  W. Crown,et al.  Issues in the Registration of Database Studies. , 2020, Journal of clinical epidemiology.

[15]  Sudha R. Raman,et al.  Linking electronic health data in pharmacoepidemiology: Appropriateness and feasibility , 2020, Pharmacoepidemiology and drug safety.

[16]  Sudha R. Raman,et al.  Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting , 2019, Pharmacoepidemiology and drug safety.

[17]  S. Schneeweiss,et al.  Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride , 2019, Diabetes Care.

[18]  J. Rassen,et al.  Graphical Depiction of Longitudinal Study Designs in Health Care Databases , 2019, Annals of Internal Medicine.

[19]  H. Dolk,et al.  The ENCePP Code of Conduct: A best practise for scientific independence and transparency in noninterventional postauthorisation studies , 2019, Pharmacoepidemiology and drug safety.

[20]  Olaf Klungel,et al.  The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE) , 2018, British Medical Journal.

[21]  Jesper Hallas,et al.  Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study , 2018, British Medical Journal.

[22]  Xin Sun,et al.  Real world evidence: experience and lessons from China , 2018, British Medical Journal.

[23]  J. Udell,et al.  Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor , 2018, Circulation.

[24]  S. Suissa.  Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias. , 2018, Circulation.

[25]  Xavier Kurz,et al.  Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) , 2018, Pharmacoepidemiology and drug safety.

[26]  David Madigan,et al.  Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making , 2017, Pharmacoepidemiology and drug safety.

[27]  K. Khunti,et al.  Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs , 2017, Circulation.

[28]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[29]  N. Dreyer,et al.  The GRACE Checklist: A Validated Assessment Tool for High Quality Observational Studies of Comparative Effectiveness , 2016, Journal of managed care & specialty pharmacy.

[30]  James M Robins,et al.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.

[31]  S. Anderson,et al.  The FDA's sentinel initiative—A comprehensive approach to medical product surveillance , 2016, Clinical pharmacology and therapeutics.

[32]  C Daniel Mullins,et al.  A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[33]  C Barbui,et al.  What is the European Medicines Agency? , 2012, Epidemiology and Psychiatric Sciences.

[34]  Uwe Siebert,et al.  Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retr , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[35]  David Atkins,et al.  Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[36]  Michael L. Johnson,et al.  Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[37]  M. Epstein,et al.  Guidelines for good pharmacoepidemiology practices (GPP) , 2008 .

[38]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[39]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.

[40]  Samy Suissa,et al.  Immortal time bias in observational studies of drug effects , 2007, Pharmacoepidemiology and drug safety.

[41]  A. Arana,et al.  Guide on methodological standards in pharmacoepidemiology , 2016 .

[42]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[43]  Guideline on good pharmacovigilance practices ( GVP ) Module , 2013 .

[44]  K. Vrangbæk,et al.  Steering Committee , 2006, ASE.